NEW YORK (TheStreet) -- CHANGE IN RATINGS
upgraded at Citigroup from Hold to Buy. $82 price target. Seeing signs of significant demand recovery, which should boost retail margins.
downgraded at Barclays to Underweight from Equal Weight. Maintain $32 price target. 2009 and 2010 EPS estimates boosted to $3.30 and $2.90, respectively.
downgraded at Goldman from Buy to Neutral. Stock was also removed from the Conviction List. Expect the company to give conservative 2010 guidance.
upgraded at Morgan Stanley from Underweight to Overweight. $111 price target. Estimates also raised, as the company should also gain market share in 2010.
East West Bancorp
downgraded at FBR from Outperform to Market Perform. $16 price target. Valuation call, even though estimates were also raised.
upgraded at Goldman from Neutral to Buy. The stock was also add to the Conviction List, as the group is firing on all cylinders.
Human Genome Sciences
downgraded at Goldman from Buy to Neutral. Valuation call, as the stock is up 62%.
Helmerich & Payne
upgraded at Goldman from Neutral to Buy. Land rig market is tightening up.
upgraded at Goldman from Sell to Neutral. Stock is already pricing in weak fundamentals. $28 price target.
upgraded at Barclays to Overweight from Equal Weight on potential upside throughout 2010. Price target raised by a dollar to $26. 2009 and 2010 EPS estimate improved to $1.18 and $1.50, respectively.
estimates raised at Goldman through 2011. Company is realizing higher margins. Neutral rating and $19 price target.
downgraded at Goldman from Buy to Neutral. Stock is up 166% since March. $18 price target.
downgraded at Goldman from Buy to Neutral. Valuation call, based on a $20 price target.
upgraded at Goldman from Sell to Neutral. Utilization is improving in the land rig market.
downgraded at Goldman from Buy to Neutral. Valuation call, as the stock is up 89% since July.
downgraded at Barclays to Equal Weight from Overweight on valuation. Price target trimmed to $42 from $45. 2009 EPS estimate raised to $2.74, 2010 cut to $2.90.
downgraded at Morgan Stanley from Overweight to Equal-weight. Estimates also cut, as same-store sales are falling across the industry.
upgraded at Keybanc from Hold to Buy. $21 price target. Steel processing volume and metal price spread are improving faster than expected.
numbers boosted at Goldman. Shares of WOR now seen reaching $14. Estimates also raised, to reflect higher steel prices and cost-cutting. Neutral rating.
downgraded at Goldman from Buy to Neutral. Valuation call, based on a $67 price target.
STOCK COMMENTS / EPS CHANGES
target raised at UBS. Shares of AFL now seen reaching $52. Investment losses appear manageable. Neutral rating.
estimates, target cut at Morgan Stanley. Shares of AMTD now seen reaching $28. Estimates also lowered, to reflect price competition in trade commissions. Overweight rating.
Abercrombie & Fitch
cut from Conviction Buy List at Goldman. Estimates also lowered, to reflect lower sales and margin pressure. Buy rating and new $39 price target.
estimates lowered at UBS through 2011. Company will increase investment spending. Buy rating and $120 price target.
estimates increased at Goldman through 2011. Company is seeing higher sales, but still faces risks with its fashion shift. Sell rating and $24 price target.
numbers raised at Citigroup. Shares of CBE now seen reaching $51. Estimates also boosted, to reflect higher planned capital spending by customers. Buy rating.
estimates boosted at Barclays. Barclays raised COLM 2009 and 2010 EPS estimates to $1.70 and $2.05, respectively. Reiterate Overweight rating and $52 target.
added to Conviction Buy List at Goldman. Stock is replacing COV. The company is the only one in the group with a significant new product cycle. New $112 price target.
target higher, estimates cut at Barclays. Barclays raised FST price target to $28 from $25. 2009 and 2010 EPS estimates dropped to $1.90 and $1.85, respectively. Reiterate Overweight rating.
numbers raised at Goldman through 2012. US transaction trends are improving and margins have moved higher, though Canada remains weak. Neutral rating and new $53 price target.
estimate tweaked at Barclays. 2011 EPS estimate lifted to $0.46, 2010 maintained at $0.38. Reiterate Equal Weight rating and $7 price target.
price target increased at Barclays. Barclays raised PKD price target by a dollar to $7. 2009 and 2010 EPS maintained at $0.14 and $0.10, respectively. Equal Weight rating.
estimates, target raised at Goldman. SCHN estimates were increased through 2012. Prospects are improving in the company's auto parts business. Neutral rating and $48 price target.
estimate cut at Barclays. SCHW 2010 EPS estimate lowered 4 cents to $0.84. Equal Weight rating and $18 price target.
numbers lowered at Morgan Stanley through 2011. Estimates also cut, to reflect new pricing for equity and ETF trades. Overweight rating.
numbers boosted at Goldman through 2012. Company is seeing higher sales. Sell rating and new $61 price target.
estimate lowered at Barclays. SPW 2010 EPS estimate plunged to $3.70 from $4.20. Reiterate Overweight rating and $90 price target.
numbers reduced at Goldman. Shares of STZ now seen reaching $15. Estimates also lowered, as wine sales remain soft. Neutral rating.
estimate slashed at Barclays. Barclays cut TXT 2010 EPS estimate to $0.65 from $0.90. Reiterate Overweight rating and $28 price target.
estimate lowered at Barclays. 2009 EPS estimate trimmed to $2.39, 2010 maintained at $2.40. Equal Weight rating and $35 price target.
estimate cut at Barclays. Barclays lowered WCC 2010 EPS estimate to $2.40 from $2.75. Maintain Overweight rating and $45 price target.
This article was written by a staff member of TheStreet.com.